Clinical Trial Update: Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a modified XELOX regimen as first-line therapy for metastatic colorectal cancer, reporting on efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Colorectal Adenocarcinoma | Phase 2 | Status: UNKNOWN